NIH | National Cancer Institute | NCI Wiki  

Date

Meeting cancelled.

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Musk, Philip (NIH/NCI) [C]

X
Warren Kibbe

Kim, Erika (NIH/NCI) [E]


Gregory Tawa

William Hendriks

Matthew Breen
X
Roel Verhaak



Goals

  • Review, discuss, and prioritize ICDC study submission proposals

Outstanding Action items

Agenda

Discussion ItemWhoNotes
Study Queue

Musk, Philip (NIH/NCI) 

  • OSA04: 
    • Osteosarcoma study from Auburn University
    • 7 cases
    • Clinical and Transcriptomic data
    • Approved by the SAC on 9/20/23
  • COTC021: Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma
    • This is the parallel arm to COTC022: SOC in dogs with Osteosarcoma that was previously uploaded to the ICDC
    • Clinical data for 152 dogs. mRNAseq for 93 dogs
    • Status: Approved by SAC on 6/30/23, Template-based data loading files have been received, file transfer (fastq) is complete, however md5 sums and files sizes were not provided in the requested format compatible with the ICDC system
  • UBC03
    • Approved by SAC on 8/13/22
    • "Transcriptomic analyses of early stage bladder cancer in Scottish Terriers detected through screening"
    • Purdue University
    • 19 cases
    • Status: v4 template-based data loading files have been reviewed, edits to be requested soon
  • OSA02
    • Approved by SAC on 9/22/22
    • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma"
    • Colorado State University
    • 108 cases
    • Status: Template-based loading files have been received and reviewed and there is a call set up to resolve minor issues
  • PRECINCT01 
    • Approved by SAC on 6/28/22
    • "Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases"
    • UC Davis
    • 21 cases
    • Status: Pathology reports and adverse event data have been indexed by DCF, the study is pending testing by the ICDC team
  • PRECINCT02
    • Approved by SAC on 12/8/22
    • "Novel treatments for Diffuse large B cell lymphoma (DLBCL) in dogs"
    • Tufts University
    • 49 cases
    • Status: Updated/corrected adverse event, visit, vital signs and physical exam data received
  • PANCAN01
    • Approved by SAC on 11/8/21
    • "Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds"
    • University of Georgia
    • 684 cases
    • Status: Submitters generating template-based loading files, data manager PoC has been identified, candidate study has been identified to move forward

Minutes (Not Verbatim)



Action items